Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin vs Cisplatin in TACE for Hepatocellular Carcinoma
NCT00843934Phase 3Unknown
- Sponsor
- Nihon University
- Start
- Mar 2009
- Primary completion
- Dec 2012
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin and Cisplatin micelle injection (HA132) in hepatocellular carcinoma (HCC), sponsored by Nihon University. Status: unknown.
02
Drugs
epirubicinCisplatin micelle injection (HA132)
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00843934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843934.